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1. Introduction   
Duchenne muscular dystrophy (DMD) is the most common form of childhood muscular 
dystrophy. DMD is an X-linked recessive disorder with an incidence of one in 3500 live male 
births (Emery, 1991). DMD causes progressive degeneration and regeneration of skeletal 
and cardiac muscles due to mutations in the dystrophin gene, which encodes a 427-kDa 
subsarcolemmal cytoskeletal protein (Hoffman et al., 1987). DMD is associated with severe, 
progressive muscle weakness and typically leads to death between the ages of 20 and 35 
years. Due to recent advances in respiratory care, much attention is now focused on treating 
the cardiac conditions suffered by DMD patients. 
 
 
Fig. 1. Dystrophin-glycoprotein complex. 
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Molecular structure of the dystrophin-glycoprotein complex and related proteins 
superimposed on the sarcolemma and subsarcolemmal actin network (redrawn from 
Yoshida et al. (Yoshida et al., 2000), with modifications). cc, coiled-coil motif on 
dystrophin (Dys) and dystrobrevin (DB); SGC, sarcoglycan complex; SSPN, sarcospan; 
Syn, syntrophin; Cav3, caveolin-3; N and C, the N and C termini, respectively; G, G-
domain of laminin; asterisk indicates the actin-binding site on the dystrophin rod domain; 
WW, WW domain. 
The approximately 2.5-megabase dystrophin gene is the largest gene identified to date, and 
because of its size, it is susceptible to a high sporadic mutation rate. Absence of dystrophin 
and the dystrophin-glycoprotein complex (DGC) from the sarcolemma leads to severe 
muscle wasting (Figure 1). Whereas DMD is characterized by the absence of functional 
protein, Becker muscular dystrophy, which is commonly caused by in-frame deletions of the 
dystrophin gene, results in the synthesis of a partially functional protein. 
2. Gene-replacement strategies using virus vectors 
2.1 Choice of vector 
Successful therapy for DMD requires the restoration of dystrophin protein in skeletal and 
cardiac muscles. While various viral vectors have been considered for the delivery of genes 
to muscle fibers, the adeno-associated virus (AAV)-based vector is emerging as the gene 
transfer vehicle with the most potential for use in DMD gene therapies. The advantages of 
the AAV vector include the lack of disease associated with a wild-type virus, the ability to 
transduce non-dividing cells, and the long-term expression of the delivered transgenes 
(Okada et al., 2002). Serotypes 1, 6, 8 and 9 of recombinant AAV (rAAV) exhibit a potent 
tropism for striated muscles (Inagaki et al., 2006). Since a 5-kb genome is considered to be 
the upper limit for a single AAV virion, a series of rod-truncated micro-dystrophin genes is 
used in this treatment (Yuasa et al., 1998). 
Due to ingenious cloning and preparation techniques, adenovirus vectors are efficient 
delivery systems of episomal DNA into eukaryotic cell nuclei (Okada et al., 1998). The utility 
of adenovirus vectors has been increased by capsid modifications that alter tropism, and by 
the generation of hybrid vectors that promote chromosomal insertion (Okada et al., 2004). 
Also, gutted adenovirus vectors devoid of all adenoviral genes allow for the insertion of 
large transgenes, and trigger fewer cytotoxic and immunogenic effects than do those only 
deleted in the E1 regions (from bases 343 to 2270) (Hammerschmidt, 1999). Human artificial 
chromosomes (HACs) have the capacity to deliver a large gene (roughly 6-10 megabases) 
into host cells without integrating the gene into the host genome, thereby preventing the 
possibility of insertional mutagenesis and genomic instability (Hoshiya et al., 2008).  
A goal in clinical gene therapy is to develop gene transfer vehicles that can integrate 
exogenous therapeutic genes at specific chromosomal loci, so that insertional oncogenesis is 
prevented. AAV can insert its genome into a specific locus, designated AAVS1, on 
chromosome 19 of the human genome (Kotin et al., 1992). The AAV Rep78/68 proteins and 
the Rep78/68-binding sequences are the trans- and cis-acting elements needed for this 
reaction. A dual high-capacity adenovirus-AAV hybrid vector with full-length human 
dystrophin-coding sequences flanked by AAV integration-enhancing elements was tested 
for targeted integration (Goncalves et al., 2005).  
Gene correction is a process whereby sequence alterations in genes can be corrected by 
homologous recombination-mediated gene conversion between the recipient target locus 
www.intechopen.com
 Progress and Challenges in AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy 
 
227 
and a donor construct encoding the correct sequence (Klug, 2005). The introduction of a 
corrective sequence together with a site-specific nuclease to induce a double-stranded break 
(DSB) at sites responsible for monogenic disorders would activate gene correction. Pairs of 
designated zinc-finger protein with tandem DNA binding sites fused to the cleavage 
domain of the Fok1 protein were introduced into model systems or cell lines and produced 
corrections in 10–30% of cases tested (Porteus and Baltimore, 2003). 
2.2 Modification of the dystrophin gene and promoter 
Due to the large deletion in its genome, the gutted adenovirus vector can package 14-kb of 
full-length dystrophin cDNA. Multiple proximal muscles of seven-day-old 
utrophin/dystrophin double knockout mice (dko mice), which typically show symptoms 
similar to human DMD, were effectively transduced with the gutted adenovirus bearing 
full-length murine dystrophin cDNA (Kawano et al., 2008). However, further improvements 
are needed to regulate the virus-associated host immune response before clinical trials can 
be performed. 
 
 
Fig. 2. Structures of full-length and truncated dystrophin. 
Helper-dependent adenovirus vector can package 14-kb of full-length dystrophin cDNA 
because of the large-sized deletion in its genome. A mini-dystrophin is cloned from a patient 
with Becker muscular dystrophy, which is caused by in-frame deletions resulting in the 
synthesis of partially functional protein. A series of truncated micro-dystrophin cDNAs 
harboring only four rod repeats with hinge 1, 2, and 4 (CS1); the same components, except 
that the C-terminal domain is deleted (delta CS1); or one rod repeat with hinge 1 and 4 (M3), 
are constructed to be packaged in the AAV vector. 
A series of truncated dystrophin cDNAs containing rod repeats with hinge 1, 2, and 4 were 
constructed (Figure 2) (Yuasa et al., 1998). Although AAV vectors are too small to package 
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the full-length dystrophin cDNA, AAV vector-mediated gene therapy using a rod-
truncated dystrophin gene provides a promising approach (Wang et al., 2000). The 
structure and, particularly, the length of the rod are crucial for the function of micro-
dystrophin (Sakamoto et al., 2002). An AAV type 2 vector expressing micro-dystrophin 
(DeltaCS1) under the control of a muscle-specific MCK promoter was injected into the 
tibialis anterior (TA) muscles of dystrophin-deficient mdx mice (Yoshimura et al., 2004), 
and resulted in extensive and long-term expression of micro-dystrophin that exhibited 
improved force generation.  
The impact of codon usage optimization on micro-dystrophin expression and function in the 
mdx mouse was assessed to compare the function of two different configurations of codon-
optimized micro-dystrophin genes under the control of a muscle-restrictive promoter (Spc5-
12) (Foster et al., 2008). Codon optimization of micro-dystrophin significantly increased 
micro-dystrophin mRNA and protein levels after intramuscular and systemic 
administration of plasmid DNA or rAAV8. By randomly assembling myogenic regulatory 
elements into synthetic promoter recombinant libraries, several artificial promoters were 
isolated whose transcriptional potencies greatly exceed those of natural myogenic and viral 
gene promoters (Li et al., 1999).  
2.3 Use of surrogate genes 
An approach using a surrogate gene would bypass the potential immune responses 
associated with the delivery of exogenous dystrophin. Methods to increase expression of 
utrophin, a dystrophin paralog, show promise as a treatment for DMD. rAAV6 harboring a 
murine codon-optimized micro-utrophin transgene was intravenously administered into 
adult dko mice to alleviate the pathophysiological abnormalities (Odom et al., 2008). The 
paralogous gene efficiently acted as a surrogate for dystrophin. Myostatin is extensively 
documented as being a negative regulator of muscle growth. Systemic gene delivery of 
myostatin propeptide, a natural inhibitor of myostatin, enhanced body-wide skeletal muscle 
growth in both normal and mdx mice (Qiao et al., 2008). The delivery of various growth 
factors, such as insulin-like growth factor-I (IGF-I), has been successful in promoting skeletal 
muscle regeneration after injury (Schertzer and Lynch, 2006).  
Matrix metalloproteinases (MMPs) are key regulatory molecules in the formation, 
remodeling and degradation of all extracellular matrix (ECM) components in pathological 
processes. MMP-9 is involved predominantly in the inflammatory process during muscle 
degeneration (Fukushima et al., 2007). In contrast, MMP-2 is associated with ECM 
remodeling during muscle regeneration and fiber growth.  
3. AAV-mediated transduction of animal models 
3.1 Vector production 
When adenovirus helper plasmid is co-transfected into human embryonic kidney 293 cells 
along with a vector plasmid encoding the AAV vector and an AAV packaging plasmid 
harboring rep-cap genes, the AAV vector is produced as efficiently as when using 
adenovirus infection. A large-scale transduction method to produce AAV vectors with an 
active gassing system makes use of large culture vessels for labor- and cost-effective 
transfection in a closed system. Samples containing vector particles are further purified with 
a two-tier CsCl gradient or dual ion-exchange chromatography to obtain highly purified 
vector particles. 
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Fig. 3. A scalable triple plasmid transfection system using active gassing.  
To gain acceptance as a medical treatment with a dose of over 1x1013 genome copies 
(g.c.)/kg body weight, AAV vectors require a scalable and economical production method. 
A production protocol of AAV vectors in the absence of a helper virus (Matsushita et al., 
1998) is widely employed for triple plasmid transduction of human embryonic kidney 293 
cells (Okada et al., 2002). The adenovirus regions that mediate AAV vector replication 
(namely, the VA, E2A and E4 regions) were assembled into a helper plasmid. When this 
helper plasmid is co-transfected into human embryonic kidney 293 cells along with 
plasmids encoding the AAV vector genome and rep-cap genes, the AAV vector is produced 
as efficiently as when using adenovirus infection (Figure 3). Importantly, contamination of 
most adenovirus proteins can be avoided in AAV vector stock made by this helper virus-
free method. Samples containing vector particles are further purified with a two-tier CsCl 
gradient or dual ion-exchange chromatography to obtain highly purified vector particles 
(Okada et al., 2002).  
Despite improvements in vector production, including the development of packaging cell 
lines expressing Rep/Cap, and of methods that induce the expression and regulation of 
Rep/Cap (Okada et al., 2001), maintaining such cell lines remains difficult, as the early 
expression of Rep proteins is toxic to cells. A scalable method, using active gassing and large 
culture vessels, was developed to transfect rAAV in a closed system, in a labor- and cost-
effective manner (Okada et al., 2005). This vector production system achieved a yield of 
more than 5x1013 g.c./flask by improving gas exchange to maintain the physiological pH in 
the culture medium. Recent developments in ion-exchange chromatography also suggest 
that vector production using transduction culture supernatant would be compatible with 
current good manufacturing practice and production on an industrial scale (Okada et al., 
2009). Moreover, AAV vector production in insect cells would be compatible with current 
good manufacturing practice production on an industrial scale (Cecchini et al., 2008).  
3.2 Animal models for the gene transduction study 
Dystrophin-deficient canine X-linked muscular dystrophy was found in a golden retriever 
with a 3’ splice-site point mutation in intron 6 (Valentine et al., 1988). The clinical and 
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pathological characteristics of dystrophic dogs are more similar to those of DMD patients 
than are those of mdx mice. A beagle-based model of canine X-linked muscular dystrophy, 
which is smaller and easier to handle than the golden retriever-based muscular dystrophy 
dog (GRMD) model, has been established in Japan, and is referred to as CXMDJ (Shimatsu et 
al., 2005). The limb and temporal muscles of CXMDJ are affected by two-month-old, which is 
the age corresponding to the second peak of serum creatine kinase. 
Interestingly, we found extensive lymphocyte-mediated immune responses to rAAV2-lacZ 
after direct intramuscular injection into CXMDJ dogs, despite successful delivery of the same 
viral construct into mouse skeletal muscle (Yuasa et al., 2007). In contrast to rAAV2, rAAV8-
mediated transduction of canine skeletal muscles produced significantly higher transgene 
expression with less lymphocyte proliferation than rAAV2 (Ohshima et al., 2008).  
It is increasingly important to develop strategies to treat DMD that consider the effect on 
cardiac muscle. The pathology of the conduction system in CXMDJ was analyzed to 
establish the therapeutic target for DMD (Urasawa et al., 2008). Although dystrophic 
changes of the ventricular myocardium were not evident at the age of 1 to 13 months, 
Purkinje fibers showed remarkable vacuolar degeneration when dogs were as young as 
four-months-old. Furthermore, degeneration of Purkinje fibers was coincident with 
overexpression of Dp71 at the sarcolemma. The degeneration of Purkinje fibers could be 
associated with the distinct deep Q waves present in ECGs and the fatal arrhythmias seen in 
cases of dystrophin deficiency (Urasawa et al., 2008). 
3.3 Immunological Issues of rAAV 
Neo-antigens introduced by AAV vectors evoke significant immune reactions in DMD 
muscle, since increased permeability of sarcolemma allows leakage of the transgene 
products from the dystrophin-deficient muscle fibers (Yuasa et al., 2002). rAAV2 transfer 
into skeletal muscles of normal dogs resulted in low and transient expression, together 
with intense cellular infiltration, and the marked activation of cellular and humoral 
immune responses (Yuasa et al., 2007). Furthermore, an in vitro interferon-gamma release 
assay showed that canine splenocytes respond to immunogens or mitogens more strongly 
than do murine splenocytes. In fact, co-administration of immunosuppressants, 
cyclosporine (CSP) and mycophenolate mofetil (MMF) improved rAAV2 transduction. 
The AAV2 capsids can induce a cellular immune response via MHC class I antigen 
presentation with a cross-presentation pathway, and rAAV2 has also been proposed to 
have an effect on human dendritic cells (DCs). In contrast, other serotypes, such as 
rAAV8, induced T-cell activation to a lesser degree (Ohshima et al., 2008). 
Immunohistochemical analysis revealed that the rAAV2-injected muscles showed higher 
rates of infiltration of CD4+ and CD8+ T lymphocytes in the endomysium than the rAAV8-
injected muscles (Ohshima et al., 2008).  
Resident antigen-presenting cells, such as DCs, myoblasts, myotubes and regenerating 
immature myofibers, might play a role in the immune response. A recent study also showed 
that mRNA levels of MyD88 and co-stimulating factors, such as CD80, CD86 and type I 
interferon, are elevated in both rAAV2- and rAAV8-transduced dog DCs in vitro (Ohshima 
et al., 2008). A brief course of immunosuppression with a combination of anti-thymocyte 
globulin (ATG), CSP and MMF was effective in permitting AAV6-mediated, long-term and 
robust expression of a canine micro-dystrophin in the skeletal muscle of a dog DMD model 
(Wang et al., 2007). 
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3.4 Intravascular vector administration by limb perfusion 
Although recent studies suggest that vectors based on AAV are capable of body-wide 
transduction in rodents, translating this finding into large animals remains a challenge. 
Intravascular delivery can be performed as a form of limb perfusion, which might bypass 
the immune activation of DCs in the injected muscle (Ohshima et al., 2008). We performed 
limb perfusion-assisted intravenous administration of rAAV8-lacZ into the hind limb of 
normal dogs and rAAV8-micro-dystrophin into the hind limb of CXMDJ dogs (Figure 4) 
(Ohshima et al., 2008). Administration of rAAV8-micro-dystrophin by limb perfusion 
produced extensive transgene expression in the distal limb muscles of CXMDJ dogs without 
obvious immune responses for as long as eight weeks after injection.  
 
 
Fig. 4. Intravascular vector administration by limb perfusion. 
(A) A blood pressure cuff is applied just above the knee of an anesthetized CXMDJ dog. A 
24-gauge intravenous catheter is inserted into the lateral saphenous vein, connected to a 
three-way stopcock, and flushed with saline. With a blood pressure cuff inflated to over 300 
mmHg, saline (2.6 ml/kg) containing papaverine (0.44 mg/kg, Sigma-Aldrich, St. Louis, 
MO) and heparin (16 U/kg) is injected by hand over a 10 second period. The three-way 
stopcock is connected to a syringe containing rAAV8 expressing micro-dystrophin (1 x 1014 
vg/kg, 3.8 ml/kg). The syringe is placed in a PHD 2000 syringe pump (Harvard Apparatus, 
Edenbridge, UK). Five minutes after the papaverine/heparin injection, rAAV8 is injected at 
a rate of 0.6 ml/sec. (B) Administration of rAAV8-micro-dystrophin by limb perfusion 
produces extensive transgene expression in the distal limb muscles of CXMDJ dogs without 
obvious immune responses at four weeks after injection. 
3.5 Global muscle therapies 
In comparison with fully dystrophin-deficient animals, targeted transgenic repair of skeletal 
muscle, but not cardiac muscle, paradoxically elicits a five-fold increase in cardiac injury 
and dilated cardiomyopathy (Townsend et al., 2008). Because the dystrophin-deficient heart 
is highly sensitive to increased stress, increased activity by the repaired skeletal muscle 
provides the stimulus for heightened cardiac injury and heart remodeling. In contrast, a 
single intravenous injection of AAV9 vector expressing micro-dystrophin efficiently 
transduces the entire heart in neonatal mdx mice, thereby ameliorating cardiomyopathy 
(Bostick et al., 2008). 
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Since a number of muscular dystrophy patients can be identified through newborn 
screening, neonatal transduction may lead to an effective early intervention in DMD 
patients. After a single intravenous injection, robust skeletal muscle transduction with 
AAV9 vector throughout the body was observed in neonatal dogs (Yue et al., 2008). 
Systemic transduction was achieved in the absence of pharmacological intervention or 
immune suppression and lasted for at least six months, whereas cardiac muscle was barely 
transduced in the dogs.  
4. Safety and potential impact of clinical trials 
The initial clinical studies lay the foundation for future studies, providing important 
information about vector dose, viral serotype selection, and immunogenicity in humans. The 
first virus-mediated gene transfer for muscle disease was carried out for limb-girdle muscular 
dystrophy type 2D using rAAV1. The study, consisting of intramuscular injection of virus into 
a single muscle, was discharged to establish the safety of this procedure in phase I clinical 
trials (Rodino-Klapac et al., 2007). The first clinical gene therapy trial for DMD began in March 
2006 (Mendell et al., 2010). This was a Phase I/IIa study in which an AAV vector was used to 
deliver micro-dystrophin to the biceps of boys with DMD. The study was conducted on six 
boys with DMD, each of whom was transduced with mini-dystrophin genes in a muscle of one 
arm in the absence of serious adverse events. Interestingly, dystrophin-specific T cells were 
detected after treatment, providing evidence of transgene expression. The potential for T-cell 
immunity to self and nonself dystrophin epitopes should be considered in designing and 
monitoring experimental therapies for this disease. 
While low immunogenicity was considered a major strength supporting the use of rAAV in 
clinical trials, a number of observations have recently provided a more balanced view of this 
procedure (Manno et al., 2006). An obvious barrier to AAV transduction is the presence of 
circulating neutralizing antibodies that prevent the virion from binding to its cellular 
receptor (Scallan et al., 2006). This potential threat can be reduced by prescreening patients 
for AAV serotype-specific neutralizing antibodies or by performing procedures such as 
plasmapheresis before gene transfer. Another challenge recently revealed is the 
development of a cell-mediated cytotoxic T-cell (CTL) response to AAV capsid peptides. In 
the human factor IX gene therapy trial in which rAAV was delivered to the liver, only short-
term transgene expression was achieved and levels of therapeutic protein declined to 
baseline levels 10 weeks after vector infusion (Manno et al., 2006). This was accompanied by 
elevation of serum transaminase levels and a CTL response toward specific AAV capsid 
peptides. To overcome this response, transient immunosuppression may be required until 
AAV capsids are completely cleared. Additional findings suggest that T-cell activation 
requires AAV2 capsid binding to the heparan sulfate proteoglycan (HSPG) receptor, which 
would permit virion shuttling into a DC pathway, as cross-presentation (Vandenberghe et 
al., 2006). Exposure to vectors from other AAV clades, such as AAV8, did not activate 
capsid-specific T-cells. 
5. Challenges and limitations of related strategies 
5.1 Design of read-through drugs 
To suppress premature stop codon mutations, treatments involving aminoglycosides and 
other agents have been attempted. PTC124, a novel drug capable of suppressing premature 
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termination and selectively inducing ribosomal read-through of premature, but not normal, 
termination codons, was recently identified using nonsense-containing reporters (Welch et 
al., 2007). The selectivity of PTC124 for premature termination codons, its oral 
bioavailability and its pharmacological properties indicate that this drug may have broad 
clinical potential for the treatment of a large group of genetic disorders with limited or no 
therapeutic options.  
5.2 Modification of mRNA splicing 
By inducing the skipping of specific exons during mRNA splicing, antisense compounds 
against exonic and intronic splicing regulatory sequences were shown to correct the open 
reading frame of the DMD gene and thus to restore truncated yet functional dystrophin 
expression in vitro (Takeshima et al., 1995). Intravenous infusion of an antisense 
phosphorothioate oligonucleotide created an in-frame dystrophin mRNA via exon skipping 
in a 10-year-old DMD patient possessing an out-of-frame exon 20 deletion of the dystrophin 
gene (Takeshima et al., 2006). Moreover, the adverse-event profile and local dystrophin-
restoring effect of a single intramuscular injection of an antisense 2'-O-methyl 
phosphorothioate oligonucleotide, PRO051, in patients with DMD were explored (van 
Deutekom et al., 2007). Four patients received a dose of 0.8 mg of PRO051 in the TA muscle. 
Each patient showed specific skipping of exon 51 of dystrophin in 64 to 97% of myofibers, 
without clinically apparent adverse side effects.  
The efficacy and toxicity of intravenous injection of stable morpholino phosphorodiamidate 
(morpholino)-induced exon skipping were tested using CXMDJ dogs, and widespread 
rescue of dystrophin expression to therapeutic levels was observed (Yokota et al., 2009). 
Furthermore, a morpholino oligomer with a designed cell-penetrating peptide can 
efficiently target a mutated dystrophin exon in cardiac muscles (Wu et al., 2008).  
Long-term benefits can be obtained through the use of viral vectors expressing antisense 
sequences against regions within dystrophin gene. The sustained production of dystrophin at 
physiological levels in entire groups of muscles as well as the correction of muscular 
dystrophy were achieved by treatment with exon-skipping AAV1-U7 (Goyenvalle et al., 2004).   
5.3 Ex vivo gene therapy 
Transplantation of genetically corrected autologous myogenic cells is a possible treatment 
for DMD. Freshly isolated satellite cells transduced with lentiviral vectors expressing micro-
dystrophin were transplanted into the TA muscles of mdx mice, and these cells efficiently 
contributed to the regeneration of muscles with micro-dystrophin expression at the 
sarcolemma (Ikemoto et al., 2007). Mesoangioblasts are vessel-associated stem cells and 
might be candidates for future stem cell therapy for DMD (Sampaolesi et al., 2006). Intra-
arterial delivery of wild-type canine mesoangioblasts resulted in the extensive recovery of 
dystrophin expression, normal muscle morphology and function in the GRMD. Multipotent 
mesenchymal stromal cells (MSCs) are less immunogenic and have the potential to 
differentiate and display a myogenic phenotype (Dezawa et al., 2005).   
6. Future perspectives 
6.1 Pharmacological Intervention 
The use of a histone deacetylase (HDAC) inhibitor would likely enhance the utility of rAAV-
mediated transduction strategies in the clinic (Okada et al., 2006). In contrast to adenovirus-
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mediated transduction, the improved transduction with rAAV induced by the HDAC 
inhibitor is due to enhanced transgene expression rather than to increased viral entry. The 
enhanced transduction was proposed to be related to the histone-associated chromatin form 
of the rAAV concatemer in transduced cells. Since various HDAC inhibitors are currently 
being tested in clinical trials for many diseases, the use of such agents in rAAV-mediated 
DMD gene therapy is theoretically and practically reasonable.   
6.2 Capsid modification 
A DNA shuffling-based approach for developing cell type-specific vectors is an intriguing 
possibility to achieve altered tropism. Capsid genomes of AAV serotypes 1-9 were 
randomly reassembled using PCR to generate a chimeric capsid library (Li et al., 2008). A 
single infectious clone (chimeric-1829) containing genome fragments from AAV1, 2, 8, and 9 
was isolated from an integrin minus hamster melanoma cell line previously shown to have 
low permissiveness to AAV. 
7. Conclusion  
DMD remains an untreatable genetic disease that severely limits motility and life 
expectancy in affected children. The systemic delivery of rAAV to transduce truncated 
dystrophin is predicted to ameliorate the symptoms of DMD patients in the future. To 
translate gene transduction technologies into clinical practice, development of an effective 
delivery system with improved vector constructs as well as efficient immunological 
modulation must be established. A novel protocol that considers all of these issues would 
help improve the therapeutic benefits of DMD gene therapy.  
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